Philipp Kuhn

Title: Philipp Kuhn: Innovator in Biopharmaceuticals

Introduction

Philipp Kuhn is a notable inventor based in Braunschweig, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapies targeting specific receptors.

Latest Patents

Kuhn holds a patent titled "Compositions targeting epidermal growth factor receptor and methods for making and using the same." This patent describes antibody binding domains for the cluster of differentiation 3 T cell receptor (CD3) and the epidermal growth factor receptor (EGFR). It also includes cleavable linker sequences and protease-activatable bispecific fusion proteins, such as protease-activatable T cell engagers, along with their uses and methods of treatment. He has 1 patent to his name.

Career Highlights

Philipp Kuhn is currently employed at Amunix Pharmaceuticals, Inc., where he continues to advance his research and development efforts in the biopharmaceutical sector. His work focuses on creating innovative solutions that can improve patient outcomes.

Collaborations

Kuhn collaborates with talented professionals in his field, including Viktoriya Dubrovskaya and Eric Johansen. Their combined expertise contributes to the success of their projects and the advancement of biopharmaceutical innovations.

Conclusion

Philipp Kuhn is a distinguished inventor whose work in biopharmaceuticals is paving the way for new treatment methodologies. His contributions are vital to the ongoing evolution of medical therapies targeting critical receptors.